<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=2023070 81 14047&amp;ff=20230921060905&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC- &amp;utm_source=Chrome<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20230921060905&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 21 日星期四 10:09:07 +0000</lastbuilddate><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>无传统可改变危险因素的患者冠状动脉粥样硬化的临床路径：JACC 最先进的综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>降低标准可改变心血管危险因素 (SMuRF) 的发生率和患病率对于解决全球冠状动脉疾病 (CAD) 负担至关重要。然而，尽管没有 SMuRF，仍有大量个体出现冠状动脉粥样硬化。无 SMuRF 的心肌梗塞患者据观察，与患有至少 1 SMuRF 的亲属相比，其早期死亡率出乎意料地更高。这些患者最佳管理的证据是…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1343-1359.doi:10.1016/j.jacc.2023.06.045。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">降低标准可改变心血管危险因素 (SMuRF) 的发生率和患病率对于解决全球冠状动脉疾病 (CAD) 负担至关重要。然而，尽管没有 SMuRF，仍有大量个体出现冠状动脉粥样硬化。无 SMuRF 的心肌梗塞患者据观察，与至少 1 个 SMuRF 的学分相比，这些患者的早期死亡率出乎意料地更高。缺乏对这些患者进行最佳治疗的证据。我们组建了一个国际多学科团队，为无 SMuRF CAD 患者开发基于证据的临床路径。应用了改良的德尔菲法。由此产生的途径确认了潜在的动脉粥样硬化和真正的 SMuRFless 状态，确保基于证据的二级预防，并考虑对不太典型的贡献者进行额外的测试和干预。这条专门针对以前被忽视的 CAD 人群的途径，并附有登记册，旨在通过加强对循证二级预防的遵守以及对观察到的可改变风险因素的额外诊断来改善结果。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730292</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.045>10.1016/j.jacc.2023.06.045</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730292</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>杰玛·无花果树</dc:creator><dc:creator>斯蒂芬·T·弗农</dc:creator><dc:creator>贾森·哈默</dc:creator><dc:creator>迈克尔·P·格雷</dc:creator><dc:creator>克莱尔·阿诺特</dc:creator><dc:creator>埃里克·巴乔尔</dc:creator><dc:creator>詹尼·巴尔沙</dc:creator><dc:creator>大卫·布里格</dc:creator><dc:creator>亚历克斯·布朗</dc:creator><dc:creator>大卫·塞勒马杰</dc:creator><dc:creator>基思·M·查农</dc:creator><dc:creator>尼古拉斯·WS·周</dc:creator><dc:creator>詹姆斯·JH·庄</dc:creator><dc:creator>克拉拉·周</dc:creator><dc:creator>彼得·西斯图利</dc:creator><dc:creator>帕特里克·埃利诺</dc:creator><dc:creator>斯图尔特·M·格里夫</dc:creator><dc:creator>托马斯·J·古兹克</dc:creator><dc:creator>埃米尔·哈格斯特罗姆</dc:creator><dc:creator>艾丽西亚·詹金斯</dc:creator><dc:creator>加里·詹宁斯</dc:creator><dc:creator>安东尼·C·基奇</dc:creator><dc:creator>凯瑟琳·科特</dc:creator><dc:creator>伦纳德·克里萨里德斯</dc:creator><dc:creator>妈妈妈妈</dc:creator><dc:creator>罗克珊娜·迈赫兰</dc:creator><dc:creator>彼得·J·米克尔</dc:creator><dc:creator>普拉迪普·纳塔拉詹</dc:creator><dc:creator>根岸一明</dc:creator><dc:creator>约翰·奥沙利文</dc:creator><dc:creator>桑杰·帕特尔</dc:creator><dc:creator>彼得·J·帕萨尔蒂斯</dc:creator><dc:creator>朱莉·雷德芬</dc:creator><dc:creator>菲利普·G·施泰格</dc:creator><dc:creator>大卫·沙利文</dc:creator><dc:creator>约翰·桑德斯特伦</dc:creator><dc:creator>比尔吉特·沃格尔</dc:creator><dc:creator>安德鲁·威尔逊</dc:creator><dc:creator>黄丹尼斯</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>贾森·C·科瓦西奇</dc:creator><dc:creator>斯蒂芬·尼科尔斯</dc:creator><dc:creator>面向 CAD 协作者的 CRE</dc:creator><dc:date> 2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>无传统可改变危险因素的患者冠状动脉粥样硬化的临床路径：JACC 最先进的综述</dc:title><dc:identifier>下午:37730292</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.045</dc:identifier></item><item><title>儿童医疗补助受益人心脏手术后的慢性药物负担</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>结论：接受心脏手术的儿童在整个童年时期都会经历较高的药物负担。了解慢性药物使用情况可以告知婴儿（儿科医生和亚专科医生）和政策制定者，并最终了解护理这一医学复杂人群的价值。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1331-1340.doi:10.1016/j.jacc.2023.06.046。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：先天性心脏病是最常见且资源密集型的出生缺陷。随着先天性心脏病儿童越来越多地存活到幼儿期之后，了解纵向疾病负担势在必行。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是调查纽约州儿科医疗补助参与者的长期门诊处方药使用情况和支出，比较接受心脏手术的儿童（心脏参与者）和一般儿科人群。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这是一项使用纽约州先天性心脏手术纵向结果和资源利用数据库合作组织（2006-2019）对所有年龄&lt;18岁的医疗补助参与者进行的回顾性队列研究。主要结果是每人每年的慢性药物总量，每 100 人每年使用 ≥1 种和 ≥3 种药物的参与者，以及每人每年的药物支出。我们描述并比较了心脏参与者和一般儿科人群之间的结果。在心脏参与者中，多变量回归检查了结果与临床特征之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们纳入了 5,459 名接受过心脏手术的儿童（32,131 人年）和 450 万名未接受心脏手术的儿童（2200 万人年）。每 10 名接受心脏手术的儿童中，超过 4 名使用了 ≥ 1 种慢性药物，而大约每 10 名儿童中就有 1 名未接受过心脏手术。与非心脏参与者相比，每人每年的心脏药物支出高出 10 倍。在心脏参与者中，疾病严重程度与长期药物使用相关；使用率在婴儿中最高；然而，近一半的青少年使用≥1种慢性药物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：接受心脏手术的儿童在整个童年时期都会经历较高的药物负担。了解慢性药物使用情况可以告知婴儿（儿科医生和亚专科医生）和政策制定者，并最终了解护理这一医学复杂人群的价值。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730290</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.046>10.1016/j.jacc.2023.06.046</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730290</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>乔伊斯·L·胡</dc:creator><dc:creator>凯瑟琳·纳什</dc:creator><dc:creator>凯西·德拉甘</dc:creator><dc:creator>莎拉·克鲁克</dc:creator><dc:creator>马修·尼德尔</dc:creator><dc:creator>史蒂芬·库克</dc:creator><dc:creator>爱德华·汉南</dc:creator><dc:creator>马歇尔·雅各布斯</dc:creator><dc:creator>安德鲁·B·戈德斯通</dc:creator><dc:creator>克里斯托弗·J·佩蒂特</dc:creator><dc:creator>罗伯特·文森特</dc:creator><dc:creator>凯瑟琳·沃尔什·斯彭豪威尔</dc:creator><dc:creator>拉尔夫·莫斯卡</dc:creator><dc:creator>TK 苏希尔·库马尔</dc:creator><dc:creator>尼尔·德韦吉安</dc:creator><dc:creator>史蒂文·卡梅尼尔</dc:creator><dc:creator>乔治·M·阿尔菲里斯</dc:creator><dc:creator>迈克尔·F·斯沃茨</dc:creator><dc:creator>大卫·迈耶</dc:creator><dc:creator>艾琳·保罗</dc:creator><dc:creator>简·W·纽伯格</dc:creator><dc:creator>约翰·比林斯</dc:creator><dc:creator>马修·M·戴维斯</dc:creator><dc:creator>布雷特·R·安德森</dc:creator><dc:creator>纽约州先天性心脏外科纵向结果和资源利用合作组织 (CHS-COLOUR)</dc:creator><dc:date> 2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>儿童医疗补助受益人心脏手术后的慢性药物负担</dc:title><dc:identifier>下午:37730290</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.046</dc:identifier></item><item><title>年轻人的肾功能受损和主要心血管事件</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>结论：在年轻人中，eGFR 低于年龄预期值与 MACE 和 MACE+ 风险升高相关，需要进行适合年龄的风险分层、主动监测和及时干预。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1316-1327.doi:10.1016/j.jacc.2023.07.012。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：年轻人（18-39 岁）的心血管 (CV) 疾病呈上升趋势。肾功能亚临床下降（即估计肾小球滤过率 [eGFR] 是否高于当前慢性肾病阈值但低于年龄）预期值）与心血管风险升高的相关性尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是探讨患有主要不良心血管事件 (MACE) 和 MACE 合并心力衰竭 (MACE+) 的年轻人亚临床 eGFR 降低与年龄相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用加拿大安大略省的关联省级医疗保健数据集（2008 年 1 月至 2021 年 3 月）对 870 万人（360 万人年龄在 18-39 岁）进行回顾性队列研究。Cox 模型用于检查分类之间的关联eGFR (50-120 mL/min/1.73 m <sup>2</sup> ) 与 MACE（心血管死亡、急性冠脉综合征和缺血性中风的首位）和 MACE+，根据年龄分层（18-39、40-49 和 50-65 岁） ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在研究队列中（平均年龄 41.3 岁；平均 eGFR 104.2 mL/min/1.73 m <sup>2</sup> ；中位随访时间 9.2 年），早在 eGFR &lt;80 时就观察到 MACE 和 MACE+ 的相对风险逐步增加年轻人中的 mL/min/1.73 m <sup>2</sup> （例如，对于 MACE，eGFR 70-79 mL/min/1.73 m <sup>2</sup> ，年龄 18-30 岁：每 1,000 人年 2.37 次事件 [HR：1.31；95% CI： 40-49 岁：每 1,000 人年 6.26 起事件 [HR：1.09；95% CI：1.06-1.12]；50-65 岁：每 1,000 人年 14.9 起事件 [HR：1.07；95% CI：1.05-1.08 ]). 每个 MACE 组成部分和其他分析（根据过去的 CV 疾病分层，考虑指数蛋白尿，并使用重复的 eGFR 测量）的结果仍然存在。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在年轻人中，eGFR 低于年龄预期值与 MACE 和 MACE+ 风险升高相关，需要进行适合年龄的风险分层、主动监测和及时干预。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730288</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.012>10.1016/j.jacc.2023.07.012</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730288</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>朱奈德·侯赛因</dc:creator><dc:creator>哈里斯·伊姆西罗维奇</dc:creator><dc:creator>马克·坎尼</dc:creator><dc:creator>爱德华·G·克拉克</dc:creator><dc:creator>梅根·埃利奥特</dc:creator><dc:creator>彼得罗·拉瓦尼</dc:creator><dc:creator>彼得·塔努塞普特罗</dc:creator><dc:creator>阿尤布·阿克巴里</dc:creator><dc:creator>格雷戈里·L·洪德默</dc:creator><dc:creator>蒂姆·拉姆齐</dc:creator><dc:creator>纳夫迪普·唐格里</dc:creator><dc:creator>格雷格·诺尔</dc:creator><dc:creator>曼尼什·M·苏德</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>年轻人的肾功能受损和主要心血管事件</dc:title><dc:identifier>下午：37730288</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.012</dc:identifier></item><item><title>心脏手术后围术期心肌损伤/梗塞：诊断标准需要改变</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1313-1315.doi:10.1016/j.jacc.2023.08.001。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730287</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.001>10.1016/j.jacc.2023.08.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730287</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> P·J·德弗罗</dc:creator><dc:creator>理查德·惠特洛克</dc:creator><dc:creator>安德烈·拉米</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心脏手术后围术期心肌损伤/梗塞：诊断标准需要改变</dc:title><dc:identifier>下午：37730287</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.001</dc:identifier></item><item><title>高敏心肌肌钙蛋白 T 与心脏手术后 30 天和 5 年死亡率的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>结论：围手术期 hs-cTnT 释放反映的 PMI 与预期 30 天死亡率相关，但与 5 年死亡率无关。确定与生存相关的 PMI 的术后 hs-cTnT 临界值高于当前定义中建议的值。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1301-1312.doi:10.1016/j.jacc.2023.07.011。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心脏手术后围手术期心肌损伤 (PMI) 与 30 天死亡率和长期生存率的相关性仍有待确定。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究评估了心脏手术后 PMI（通过术后肌钙蛋白释放反映）与 30 天死亡率和长期生存率之间的关系：1) 冠状动脉旁路移植术 (CABG)；2) 离体主动脉瓣置换术 (AVR)手术；以及 3) 所有其他心脏手术。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对连续队列的 8,292 例接受心脏手术的患者进行围手术期高敏心肌肌钙蛋白 T (hs-cTnT) 测量进行回顾性分析，分析术后 hs-cTnT 释放与 30 天死亡率或 5 年死亡率之间的关系使用 Cox 比例风险模型对 EuroSCORE II 进行调整后，确定了孤立 CABG (32.3%)、AVR (14%) 和其他心脏手术 (53.8%) 的 30 天和 5 年死亡率的 hs-cTnT 阈值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：高术后 hs-cTnT 水平与较高的 30 天死亡率相关，但与 5 年死亡率无关。在 CABG 中，术后 hs-cTnT 的中位峰浓度为 1,044 ng/L，在 AVR 中为 502 ng/L，在在其他心脏手术中，该值为 1,110 ng/L。定义与死亡率相关的 PMI 的 hs-cTnT 阈值如下：对于 CABG，为 2,385 ng/L（170×看似健康人群中正常参考上限的 170 倍 [URL]）；对于 AVR，568 ng/L (41× URL)；对于其他心脏手术，1,873 ng/L (134× URL)。hs-cTnT 水平高于截止值导致 CABG 30 天死亡率的 HR 为 12.56（ P &lt; 0.001)，AVR 为 4.44 (P = 0.004)，其他心脏手术为 3.97 (P &lt; 0.001)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：围手术期 hs-cTnT 释放反映的 PMI 与预期 30 天死亡率相关，但与 5 年死亡率无关。确定与生存相关的 PMI 的术后 hs-cTnT 临界值高于当前定义中建议的值。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730286</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.011>10.1016/j.jacc.2023.07.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730286</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>利奥·波尔兹尔</dc:creator><dc:creator>克莱门斯·恩格勒</dc:creator><dc:creator>菲利普·斯特辛格</dc:creator><dc:creator>罗尼娅·洛曼</dc:creator><dc:creator>菲利克斯·内格勒</dc:creator><dc:creator>雅各布·赫希</dc:creator><dc:creator>迈克尔·格雷伯</dc:creator><dc:creator>乔纳斯·埃德</dc:creator><dc:creator>塞巴斯蒂安·雷因斯塔德勒</dc:creator><dc:creator>尼古拉·萨普勒</dc:creator><dc:creator>朱莉安·基洛</dc:creator><dc:creator>伊万·坦切夫斯基</dc:creator><dc:creator>塞巴斯蒂安·巴赫曼</dc:creator><dc:creator>汉内斯·阿布法尔特雷尔</dc:creator><dc:creator>埃尔弗里德·鲁特曼-乌尔默</dc:creator><dc:creator>汉诺·乌尔默</dc:creator><dc:creator>安德里亚·格里斯马赫</dc:creator><dc:creator>塞缪尔·休茨</dc:creator><dc:creator>马蒂亚斯蒂尔曼</dc:creator><dc:creator>阿克塞尔·鲍尔</dc:creator><dc:creator>迈克尔·格林</dc:creator><dc:creator>尼古拉斯·博纳罗斯</dc:creator><dc:creator>约翰内斯·霍尔菲尔德</dc:creator><dc:creator>Can Gollmann-Tepeköylü</dc:creator><dc:date> 2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>高敏心肌肌钙蛋白 T 与心脏手术后 30 天和 5 年死亡率的关系</dc:title><dc:identifier>下午：37730286</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.011</dc:identifier></item><item><title>对 5,000 名继发性二尖瓣反流患者进行经导管边对边修复：COAPT 批准后研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730284/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>结论：这项大型、当代、现实世界的研究增强了 MitraClip 系统在 SMR 患者中的安全性和有效性，包括符合 COAPT 或 MITRA-FR RCT 纳入/排除标准的患者以及被排除在 RCT 之外的患者。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1281-1297.doi:10.1016/j.jacc.2023.07.015。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：由于仔细的患者选择和 MITRA-FR 的对比结果，COAPT（功能性二尖瓣反流心力衰竭患者的 MitraClip 经皮治疗的心血管结果评估）随机对照试验 (RCT) 的实际适用性一直存在争议。 （经皮二尖瓣修复 MitraClip 装置治疗严重继发性二尖瓣反流患者的多中心研究）RCT。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：COAPT-PAS（COAPT 批准后研究）旨在评估 MitraClip 在继发性二尖瓣反流 (SMR) 患者中的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：COAPT-PAS 是一项前瞻性、单臂、观察性研究，研究对象为 2019 年至 2020 年参与 TVT（经导管瓣膜治疗）登记的 406 个美国中心接受 MitraClip 治疗的连续 5,000 名 SMR 患者。报告了 COAPT-PAS 完整队列以及符合 RCT 纳入/排除标准的 COAPT 样和 MITRA-FR 样亚组。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与 COAPT 或 MITRA-FR RCT 中的患者相比，COAPT-PAS 中的患者有更多的合并症、更严重的心力衰竭和功能限制，以及指南指导的药物治疗更少。 (n = 991) 和 MITRA-FR 类 (n = 917) 亚组的 MitraClip 植入率达到 97.7%，二尖瓣反流在 1 年时类似且持久地减少至 ≤2+（90.7%、89.7% 和 86.6%）分别），1 年时生活质量大幅改善（堪萨斯城心肌病问卷 +29 COAPT-PAS、+27 COAPT 样和 +33 MITRA-FR 样）、更快的手术时间、相似或更少的临床事件与随机对照试验的 MitraClip 组相比，临床事件发生率低于随机对照试验的仅以指南为指导的药物治疗组。COAPT-PAS 组的一年心力衰竭住院率为 18.9%，COAPT 类组为 19.7%，COAPT 类组为 24.9% COAPT-RCT 中为 28.7%，COAPT-PAS-MITRA-FR-like 中为 28.7%，而 MITRA-FR-RCT 中为 47.4%。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项大型、当代、现实世界的研究增强了 MitraClip 系统在 SMR 患者中的安全性和有效性，包括符合 COAPT 或 MITRA-FR RCT 纳入/排除标准的患者以及被排除在 RCT 之外的患者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730284/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730284</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.015>10.1016/j.jacc.2023.07.015</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730284</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>卡西什·戈尔</dc:creator><dc:creator>乔安·林登菲尔德</dc:creator><dc:creator>拉吉·马卡</dc:creator><dc:creator>赫什奈克</dc:creator><dc:creator>萨蒂亚·阿特马库里</dc:creator><dc:creator>保罗·马奥尼</dc:creator><dc:creator>迈克尔·莫尔斯</dc:creator><dc:creator>维诺德·H·图拉尼</dc:creator><dc:creator>普拉迪普·亚达夫</dc:creator><dc:creator>韦恩·巴彻勒</dc:creator><dc:creator>贾森·罗杰斯</dc:creator><dc:creator>布赖恩·惠森南特</dc:creator><dc:creator>迈克尔·里纳尔迪</dc:creator><dc:creator>詹姆斯·赫米勒</dc:creator><dc:creator>布莱恩·R·林德曼</dc:creator><dc:creator>科林·M·巴克</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>对 5,000 名继发性二尖瓣反流患者进行经导管边对边修复：COAPT 批准后研究</dc:title><dc:identifier>下午:37730284</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.015</dc:identifier></item><item><title>答复：乙酰唑胺治疗急性失代偿性心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):e113.doi:10.1016/j.jacc.2023.07.016。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730297</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.016>10.1016/j.jacc.2023.07.016</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730297</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>弗雷德里克·H·韦尔布鲁格</dc:creator><dc:creator>彼得·马滕斯</dc:creator><dc:creator>威尔弗里德·穆伦斯</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>答复：乙酰唑胺治疗急性失代偿性心力衰竭</dc:title><dc:identifier>下午:37730297</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.016</dc:identifier></item><item><title>乙酰唑胺治疗急性失代偿性心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):e111.doi:10.1016/j.jacc.2023.06.048。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730296</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.048>10.1016/j.jacc.2023.06.048</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730296</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>拉姆达斯·G·派</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>乙酰唑胺治疗急性失代偿性心力衰竭</dc:title><dc:identifier>下午:37730296</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.048</dc:identifier></item><item><title>社会经济背景对幼儿期心血管健康促进的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1377-1379.doi:10.1016/j.jacc.2023.07.014。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730295</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.014>10.1016/j.jacc.2023.07.014</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730295</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>阿玛亚·德·科斯-甘多伊</dc:creator><dc:creator>格洛丽亚·桑托斯·贝尼特</dc:creator><dc:creator>帕特里夏·博德加</dc:creator><dc:creator>豪尔赫·巴克斯特</dc:creator><dc:creator>拉克尔·迪亚兹-穆尼奥斯</dc:creator><dc:creator>克里斯托弗·希尔</dc:creator><dc:creator>伊莎贝尔·卡瓦哈尔</dc:creator><dc:creator>卡洛斯·佩拉</dc:creator><dc:creator>罗德里戈·费尔南德斯·希门尼斯</dc:creator><dc:creator>瓦伦丁·福斯特</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>社会经济背景对幼儿期心血管健康促进的影响</dc:title><dc:identifier>下午：37730295</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.014</dc:identifier></item><item><title>心血管护理伦理：行动呼吁</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1373-1376.doi:10.1016/j.jacc.2023.08.004。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730294</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.004>10.1016/j.jacc.2023.08.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730294</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>豪尔赫·R·阿莱格里亚</dc:creator><dc:creator>B哈德利·威尔逊</dc:creator><dc:creator>R·斯科特·赖特</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心血管护理伦理：行动呼吁</dc:title><dc:identifier>下午:37730294</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.004</dc:identifier></item><item><title>评估治疗效果的广义成对比较：JACC 本周评论主题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>首次事件发生时间复合终点分析在评估心血管临床试验中的治疗效果方面存在众所周知的缺点，它不能充分描述治疗的临床益处，因为事件的严重程度、随时间重复的事件以及临床情况。无法考虑相关的非生存结果。广义成对比较 (GPC) 方法通过包含最能捕捉到的任何数量和类型的结果，增加了定义主要终点的灵活性... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1360-1372.doi:10.1016/j.jacc.2023.06.047。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">首次事件发生时间复合终点分析在评估心血管临床试验中的治疗效果方面存在众所周知的缺点，它不能充分描述治疗的临床益处，因为事件的严重程度、随时间重复的事件以及临床情况。不能考虑相关的非生存结局。广义配对比较 (GPC) 方法通过包括与标准护理相比最能体现治疗临床获益的任何数量和类型的结局，增加了定义主要终点的灵活性。临床上重要的结局，包括出血严重程度、干预次数和生活质量，可以很容易地整合到单一分析中。GPC 中的治疗效果可以用净治疗获益、成功几率或获胜率来表示。这篇综述为以下方面提供了指导：使用 GPC 以及选择治疗效果测量来分析和报告心血管试验。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730293</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.047>10.1016/j.jacc.2023.06.047</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730293</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>约翰·维贝克</dc:creator><dc:creator>米凯尔·德巴克</dc:creator><dc:creator>简·韦尔夫特</dc:creator><dc:creator>塞缪尔·萨尔瓦乔</dc:creator><dc:creator>马可·瓦尔吉米利</dc:creator><dc:creator>帕斯卡·弗兰克斯</dc:creator><dc:creator>马克·比斯</dc:creator><dc:creator>埃德加·布伦纳</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>评估治疗效果的广义成对比较：JACC 本周评论主题</dc:title><dc:identifier>下午:37730293</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.047</dc:identifier></item><item><title>先天性心脏病的慢性药物负担很重要</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1341-1342.doi:10.1016/j.jacc.2023.07.017。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730291</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.017>10.1016/j.jacc.2023.07.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730291</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>玛丽·B·泰勒</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>先天性心脏病的慢性药物负担很重要</dc:title><dc:identifier>下午:37730291</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.017</dc:identifier></item><item><title>定期测量中青年 eGFR 和蛋白尿的时间</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1328-1330.doi:10.1016/j.jacc.2023.07.013。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730289</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.013>10.1016/j.jacc.2023.07.013</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730289</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·杜普雷兹</dc:creator><dc:creator>大卫·R·雅各布斯</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>定期测量中青年 eGFR 和蛋白尿的时间</dc:title><dc:identifier>下午:37730289</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.013</dc:identifier></item><item><title>二尖瓣经导管边对边修复术在现实世界患者中取得更大成功：还有更多需要回答的问题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730285/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1298-1300.doi:10.1016/j.jacc.2023.08.002。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730285/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37730285</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.002>10.1016/j.jacc.2023.08.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730285</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>马蒂亚斯·欧尔班</dc:creator><dc:creator>约尔格·豪斯莱特</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>二尖瓣经导管边对边修复术在现实世界患者中取得更大成功：还有更多需要回答的问题</dc:title><dc:identifier>下午：37730285</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.002</dc:identifier></item><item><title>阿尔茨海默病：从免疫治疗到免疫预防</title><link/>https://pubmed.ncbi.nlm.nih.gov/37729908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>最近的 Aβ 免疫疗法试验首次提供了明确的证据，表明从有症状患者的大脑中去除聚集的 Aβ 可以减缓阿尔茨海默病的进展。然而，这些试验中取得的临床益处并不大，这凸显了对两者更深入了解的必要性疾病机制以及早期干预致病级联的重要性。需要一种整合阿尔茨海默氏病的免疫预防策略，以便研究结果... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 17 日：S0092-8674(23)00910-8. doi: 10.1016/j.cell.2023.08.021. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">最近的 Aβ 免疫疗法试验首次提供了明确的证据，表明从有症状患者的大脑中去除聚集的 Aβ 可以减缓阿尔茨海默病的进展。然而，这些试验中取得的临床益处并不大，这凸显了对两者更深入了解的必要性疾病机制和早期干预致病级联的重要性。需要一种整合阿尔茨海默氏病的免疫预防策略，将临床试验的结果与临床前疾病模型的机制见解相结合，以选择有前途的抗体，优化干预时机，早期识别生物标志物，并减轻潜在的副作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37729908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37729908</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.021>10.1016/j.cell.2023.08.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37729908</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>马蒂亚斯·朱克</dc:creator><dc:creator>拉里·C·沃克</dc:creator><dc:date>2023-09-20</dc:date><dc:source>细胞</dc:source><dc:title>阿尔茨海默病：从免疫治疗到免疫预防</dc:title><dc:identifier>下午：37729908</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.021</dc:identifier></item><item><title>早期动物进化中神经基因表达程序的逐步出现</title><link/>https://pubmed.ncbi.nlm.nih.gov/37729907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>神经元和其他主要细胞类型程序的组装发生在动物进化的早期。我们可以通过研究长生动物等非两侧对称动物来重建这一过程。这些小型盘状动物不仅具有九种形态学描述的细胞类型并且没有神经元，而且还显示由肽分泌细胞触发的协调行为。我们利用系统发育学、染色质分析和比较单细胞研究了这些肽能细胞可能的神经亲和力…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 14 日：S0092-8674(23)00917-0. doi: 10.1016/j.cell.2023.08.027. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">神经元和其他主要细胞类型程序的组装发生在动物进化的早期。我们可以通过研究长生动物等非两侧对称动物来重建这一过程。这些小型盘状动物不仅具有九种形态学描述的细胞类型并且没有神经元，而且还显示由肽分泌细胞触发的协调行为。我们使用系统发育学、染色质分析和比较单细胞基因组学在四个长生动物中研究了这些肽能细胞可能的神经亲和力。我们发现长生动物中保守的细胞类型表达程序，包括转分化和循环群体细胞，表明活跃的细胞类型稳态。我们还发现了 14 种表达神经元相关成分的肽能细胞类型，例如源自具有神经发生特征的祖细胞的突触前支架。相比之下，海绵和栉水母等早期分支动物缺乏这种保守性我们的研究结果表明，在旁分泌细胞信号传导背景下，关键神经元发育和效应基因模块在刺胞动物/两侧对称动物神经元出现之前就已进化。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37729907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37729907</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.027>10.1016/j.cell.2023.08.027</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37729907</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>塞巴斯蒂安·R·纳勒</dc:creator><dc:creator>泽维尔·格劳-博韦</dc:creator><dc:creator>安娜玛丽亚·埃莱克</dc:creator><dc:creator>克里斯蒂娜·纳瓦雷特</dc:creator><dc:creator>达米亚诺·钱费罗尼</dc:creator><dc:creator>克里斯蒂娜·奇瓦</dc:creator><dc:creator>迪达克·卡尼亚斯·阿门特罗斯</dc:creator><dc:creator>阿拉特·马拉比亚巴雷纳</dc:creator><dc:creator>凯卡姆</dc:creator><dc:creator>爱德华·萨比多</dc:creator><dc:creator>哈拉尔德·格鲁伯-沃迪卡</dc:creator><dc:creator>贝恩德·席尔沃特</dc:creator><dc:creator>路易斯塞拉诺</dc:creator><dc:creator>阿尔诺·塞贝·佩德罗斯</dc:creator><dc:date>2023-09-20</dc:date><dc:source>细胞</dc:source><dc:title>早期动物进化中神经基因表达程序的逐步出现</dc:title><dc:identifier>下午：37729907</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.027</dc:identifier></item><item><title>心血管成像深度学习：综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37728933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921060905&amp;v=2.17.9.post6+86293ac<description>结论和相关性：深度学习有可能对 CVI 领域产生有意义的影响。深度学习不是一种威胁，而是可以被视为心血管成像仪的合作伙伴，可以减轻技术负担并提高护理效率和质量。高质量的前瞻性证据是仍然需要证明 DL CVI 系统的好处如何大于风险。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 20 日。doi：10.1001/jamacardio.2023.3142。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：在深度学习 (DL) 进步的推动下，人工智能 (AI) 有可能重塑心血管成像 (CVI) 领域。虽然用于 CVI 的 DL 仍处于起步阶段，但研究正在加速，以帮助实现这一目标跨多种模式对 CVI 进行处理、处理和/或解释，多种商业产品已投入临床使用。心血管成像仪必须熟悉 DL 系统，包括基本了解其工作原理、与其他自动化系统相比的相对优势本文的目的是以一种简单易懂的方式回顾 DL 到 CVI 的方法和应用，以揭开这一新兴技术的神秘面纱。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBSERVATIONS: At its core, DL is simply the application of a series of tunable mathematical operations that translate input data into a desired output. Based on artificial neural networks that are inspired by the human nervous system, there are several types of DL architectures suited to different tasks; convolutional neural networks are particularly adept at extracting valuable information from CVI data. We survey some of the notable applications of DL to tasks across the spectrum of CVI modalities. We also discuss challenges in the development and implementation of DL systems, including avoiding overfitting, preventing systematic bias, improving explainability, and fostering a human-machine partnership. Finally, we conclude with a vision of the future of DL for CVI. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: Deep learning has the potential to meaningfully affect the field of CVI. Rather than a threat, DL could be seen as a partner to cardiovascular imagers in reducing technical burden and improving efficiency and quality of care. High-quality prospective evidence is still needed to demonstrate how the benefits of DL CVI systems may outweigh the risks.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37728933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37728933</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3142>10.1001/jamacardio.2023.3142</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37728933</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Ramsey M Wehbe</dc:creator><dc:creator> Aggelos K Katsaggleos</dc:creator><dc:creator> Kristian J Hammond</dc:creator><dc:creator> Ha Hong</dc:creator><dc:creator> Faraz S Ahmad</dc:creator><dc:creator> David Ouyang</dc:creator><dc:creator> Sanjiv J Shah</dc:creator><dc:creator> Patrick M McCarthy</dc:creator><dc:creator> James D Thomas</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Deep Learning for Cardiovascular Imaging: A Review</dc:title><dc:identifier> pmid:37728933</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3142</dc:identifier></item><item><title> Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37728907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921060905&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Sep 20. doi: 10.1001/jamacardio.2023.3003. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To determine whether activation of β3ARs by repurposing a β3AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: The Beta3-LVH prospective, triple-blind, placebo-controlled phase 2b randomized clinical trial enrolled patients between September 12, 2016, and February 26, 2021, with a follow-up of 12 months. The trial was conducted at 10 academic hospitals in 8 countries across Europe (Germany, Poland, France, Belgium, Italy, Portugal, Greece, and the UK). Patients aged 18 years or older with or without HF symptoms (maximum New York Heart Association class II) were screened for the presence of LV hypertrophy (increased LV mass index [LVMI] of ≥95 g/m2 for women or ≥115 g/m2 for men) or maximum wall thickness of 13 mm or greater using echocardiography. Data analysis was performed in August 2022. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTERVENTION: Participants were randomly assigned (1:1) to mirabegron (50 mg/d) or placebo, stratified by the presence of atrial fibrillation and/or type 2 diabetes, for 12 months. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: The primary end points were LVMI determined using cardiac magnetic resonance imaging and LV diastolic function (early diastolic tissue Doppler velocity [E/e&#39;] ratio assessed using Doppler echocardiography) at 12 months. Patients with at least 1 valid measurement of either primary end point were included in the primary analysis. Safety was assessed for all patients who received at least 1 dose of study medication. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Of the 380 patients screened, 296 were enrolled in the trial. There were 147 patients randomized to mirabegron (116 men [79%]; mean [SD] age, 64.0 [10.2] years) and 149 to placebo (112 men [75%]; mean [SD] age, 62.2 [10.9] years). All patients were included in the primary intention-to-treat analysis. At 12 months, the baseline and covariate-adjusted differences between groups included a 1.3-g/m2 increase in LVMI (95% CI, -0.15 to 2.74; P = .08) and a -0.15 decrease in E/e&#39; (95% CI, -0.69 to 0.4; P = .60). A total of 213 adverse events (AEs) occurred in 82 mirabegron-treated patients (including 31 serious AEs in 19 patients) and 215 AEs occurred in 88 placebo-treated patients (including 30 serious AEs in 22 patients). No deaths occurred during the trial. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02599480.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37728907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37728907</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3003>10.1001/jamacardio.2023.3003</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37728907</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Jean-Luc Balligand</dc:creator><dc:creator> Dulce Brito</dc:creator><dc:creator> Oana Brosteanu</dc:creator><dc:creator> Barbara Casadei</dc:creator><dc:creator> Christophe Depoix</dc:creator><dc:creator> Frank Edelmann</dc:creator><dc:creator> Vanessa Ferreira</dc:creator><dc:creator> Gerasimos Filippatos</dc:creator><dc:creator> Bernhard Gerber</dc:creator><dc:creator> Damien Gruson</dc:creator><dc:creator> Dirk Hasenclever</dc:creator><dc:creator> Kristian Hellenkamp</dc:creator><dc:creator> Ignatios Ikonomidis</dc:creator><dc:creator> Bartosz Krakowiak</dc:creator><dc:creator> Renaud Lhommel</dc:creator><dc:creator> Masliza Mahmod</dc:creator><dc:creator> Stefan Neubauer</dc:creator><dc:creator> Alexandre Persu</dc:creator><dc:creator> Stefan Piechnik</dc:creator><dc:creator> Burkert Pieske</dc:creator><dc:creator> Elisabeth Pieske-Kraigher</dc:creator><dc:creator> Fausto Pinto</dc:creator><dc:creator> Piotr Ponikowski</dc:creator><dc:creator> Michele Senni</dc:creator><dc:creator> Jean-Noël Trochu</dc:creator><dc:creator> Nancy Van Overstraeten</dc:creator><dc:creator> Rolf Wachter</dc:creator><dc:creator> Anne-Catherine Pouleur</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial</dc:title><dc:identifier> pmid:37728907</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3003</dc:identifier></item><item><title> CD1 lipidomes reveal lipid-binding motifs and size-based antigen-display mechanisms</title><link/> https://pubmed.ncbi.nlm.nih.gov/37725977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921060905&amp;v=2.17.9.post6+86293ac<description> The CD1 system binds lipid antigens for display to T cells. Here, we solved lipidomes for the four human CD1 antigen-presenting molecules, providing a map of self-lipid display. Answering a basic question, the detection of >;2,000 CD1-lipid complexes demonstrates broad presentation of self-sphingolipids and phospholipids. Whereas peptide antigens are chemically processed, many lipids are presented in an unaltered form. However, each type of CD1 protein differentially edits the self-lipidome to... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 12:S0092-8674(23)00912-1. doi: 10.1016/j.cell.2023.08.022. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The CD1 system binds lipid antigens for display to T cells. Here, we solved lipidomes for the four human CD1 antigen-presenting molecules, providing a map of self-lipid display. Answering a basic question, the detection of >;2,000 CD1-lipid complexes demonstrates broad presentation of self-sphingolipids and phospholipids. Whereas peptide antigens are chemically processed, many lipids are presented in an unaltered form. However, each type of CD1 protein differentially edits the self-lipidome to show distinct capture motifs based on lipid length and chemical composition, suggesting general antigen display mechanisms. For CD1a and CD1d, lipid size matches the CD1 cleft volume. CD1c cleft size is more variable, and CD1b is the outlier, where ligands and clefts show an extreme size mismatch that is explained by uniformly seating two small lipids in one cleft. Furthermore, the list of compounds that comprise the integrated CD1 lipidome supports the ongoing discovery of lipid blockers and antigens for T cells.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37725977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37725977</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.022>10.1016/j.cell.2023.08.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37725977</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Shouxiong Huang</dc:creator><dc:creator> Adam Shahine</dc:creator><dc:creator> Tan-Yun Cheng</dc:creator><dc:creator> Yi-Ling Chen</dc:creator><dc:creator> Soo Weei Ng</dc:creator><dc:creator> Gautham R Balaji</dc:creator><dc:creator> Rachel Farquhar</dc:creator><dc:creator> Stephanie Gras</dc:creator><dc:creator> Clare S Hardman</dc:creator><dc:creator> John D Altman</dc:creator><dc:creator> Nabil Tahiri</dc:creator><dc:creator> Adriaan J Minnaard</dc:creator><dc:creator> Graham S Ogg</dc:creator><dc:creator> Jacob A Mayfield</dc:creator><dc:creator> Jamie Rossjohn</dc:creator><dc:creator> D Branch Moody</dc:creator><dc:date> 2023-09-19</dc:date><dc:source> Cell</dc:source><dc:title> CD1 lipidomes reveal lipid-binding motifs and size-based antigen-display mechanisms</dc:title><dc:identifier> pmid:37725977</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.022</dc:identifier></item><item><title> Life-threatening left atrioesophageal fistula complicated with catheter ablation for atrial fibrillation in a patient with aortic stent graft</title><link/> https://pubmed.ncbi.nlm.nih.gov/37725918/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921060905&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad609. doi: 10.1093/eurheartj/ehad609. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37725918/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37725918</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad609>10.1093/eurheartj/ehad609</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37725918</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Yuya Tanaka</dc:creator><dc:creator> Kenji Kuroki</dc:creator><dc:creator> Shigeaki Kaga</dc:creator><dc:date> 2023-09-19</dc:date><dc:source> European heart journal</dc:source><dc:title> Life-threatening left atrioesophageal fistula complicated with catheter ablation for atrial fibrillation in a patient with aortic stent graft</dc:title><dc:identifier> pmid:37725918</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad609</dc:identifier></item><item><title> Lack of association between fluoroquinolone and aortic aneurysm or dissection</title><link/> https://pubmed.ncbi.nlm.nih.gov/37724037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921060905&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: There was no significant difference in the risk of AA/AD in patients who were administered oral FQ compared to those administered 3GC. The study findings suggest that the use of FQ should not be deterred when clinically indicated. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad627. doi: 10.1093/eurheartj/ehad627. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: An increased risk of aortic aneurysm and aortic dissection (AA/AD) has been reported with fluoroquinolone (FQ) use. However, recent studies suggested confounding factors by indication. This study aimed to investigate the risk of AA/AD associated with FQ use. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This nationwide population-based study included adults aged ≥20 years who received a prescription of oral FQ or third-generation cephalosporins (3GC) during outpatient visits from 2005 to 2016. Data source was the National Health Insurance Service reimbursement database. The primary outcome was hospitalization or in-hospital death with a primary diagnosis of AA/AD. A self-controlled case series (SCCS) and Cox proportional hazards model were used. Self-controlled case series compared the incidence of the primary outcome in the risk period vs. the control periods. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 954 308 patients (777 109 with FQ and 177 199 with 3GC use) were included. The incidence rate ratios for AA/AD between the risk period and the pre-risk period were higher in the 3GC group [11.000; 95% confidence interval (CI) 1.420-85.200] compared to the FQ group (2.000; 95% CI 0.970-4.124). The overall incidence of AA/AD among the patients who received FQ and 3GC was 5.40 and 8.47 per 100 000 person-years. There was no significant difference in the risk between the two groups (adjusted hazard ratio 0.752; 95% CI 0.515-1.100) in the inverse probability of treatment-weighted Cox proportional hazards model. Subgroup and sensitivity analysis showed consistent results. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: There was no significant difference in the risk of AA/AD in patients who were administered oral FQ compared to those administered 3GC. The study findings suggest that the use of FQ should not be deterred when clinically indicated.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37724037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921060905&v=2.17.9.post6+86293ac">37724037</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad627>10.1093/eurheartj/ehad627</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37724037</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Kyungmin Huh</dc:creator><dc:creator> Minsun Kang</dc:creator><dc:creator> Jaehun Jung</dc:creator><dc:date> 2023-09-19</dc:date><dc:source> European heart journal</dc:source><dc:title> Lack of association between fluoroquinolone and aortic aneurysm or dissection</dc:title><dc:identifier> pmid:37724037</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad627</dc:identifier></item></channel></rss>